In this interview with FSRC, Dr. Marina Alois Njelekela (Executive Director and Chair of the Department of Physiology at Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania) shares her view on the difference novel HCV drugs would make and the challenges of providing access to HCV treatment in Tanzania. She remarks on how the lessons learnt from the successful management of HIV in the African countries can be utilized for HCV: leveraging and integrating the existing HIV infrastructure towards providing streamlined HCV treatment and care. In addition, she mentions about the possible active stakeholders for the fight against viral hepatitis in Africa.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…